This year, 2008, has been difficult for many companies in many sectors. The economic tide has been sweeping negatively across many of the world’s markets and causing business confidence to wane. The life science markets have not been immune and the impact has been palpable in many corners of the sector.
This
year, 2008, has been difficult for many companies in many sectors.
The economic tide has been sweeping negatively across many of the
world’s markets and causing business confidence to wane. The life
science markets have not been immune and the impact has been palpable
in many corners of the sector.
The
biotech industry has come under increased pressure as the climate for
early stage ventures has become even more challenging. Toxicity in
the finance markets has made fundraising through venture capital,
private equity and structured debt-financing extremely difficult. A
lack of support for listed biotech stocks have led to incredibly low
volumes of share trading on many of Europe’s exchanges, meaning the
IPO and exit opportunities for investors are heavily restricted.
Merger and acquisition activities have continued unabated and
significant deals can be seen between biotech and large-pharma, often
at premium values over current market capitalisation, further
fuelling the belief that exits are currently best achieved via these
trade-sale routes.
This
sentiment is echoed across other parts of the sector where
significant efforts are being undertaken to re-organise many of the
industry’s hallmark names in an attempt to bring about greater
efficiency, boost R&D and reduce the impact of patent expiration.
Yet among these challenges are pockets of real success, companies
growing rapidly, businesses being merged to forge new powerful
entities, products being approved, relationships between pharma and
biotech thriving.
This
challenging environment calls upon different skills and experience
and there is currently a re-ordering of hiring priorities across the
European life science markets. Career management in the current
sector requires you to be bold, clear about your direction and
confident in bringing success to your next job. There are disciplines
that are continuing to see good rates of vacancies and this
requirement illustrates that capitalising on your strengths is a
clear way to improve your sustained career development.
We
are continuing to see demand in the area of regulatory affairs as
companies prepare their organisations to deal with the rigours of new
and emerging legislation and the perceived tightening of regulations
by health authorities. Demand over recent years has created a
distinct shortage of readily available regulatory professionals with
the experience in managing regulatory development programmes, as well
as maximising the product life-cycle opportunities across global
markets.
Also,
the expanding role of regulatory affairs in supporting the
organisation has seen a growth in the number of people being
recruited into areas like regulatory intelligence and policy,
regulatory operations, early drug evaluation or due diligence. This
variety has broadened the career opportunities for regulatory affairs
professionals and has introduced new skills to the function.
This
demand has encouraged a shift in the recruiting approach of many
companies across the sector. To overcome the scarcity in regulatory
affairs skills, companies have needed to be far more versatile and
proactive in their approaches to recruiting these regulatory
candidates. It means there is now a strong reliance on International
recruiting strategies, trawling the diverse regulatory affairs talent
pool of Europe and beyond, to attain the necessary regulatory skills
to support projects. Companies have had to employ proactive
strategies to reach the candidates and aggressively pursue them,
offering different incentives to be able to attract the very best.
And while we have seen some easing in the market, the dearth of
regulatory affairs talent seems set to continue.
There
has been continued consolidation across all areas of the life science
sector in 2007 and 2008. Alongside this, we have seen major
restructure announcements that have affected companies large to
small. These significant changes in the structures of many
organisations have made Human Resource skills a central requirement
for many companies. The ability to manage the human resources of a
company in a highly effective way to ensure you are retaining your
best talent in the new efficient structures is critical. Good Human
Resource professionals have the vision to be able to see where a
company is headed and how you need to swap out the skills that are no
longer central to the company and replace them with the skills of
tomorrow and the future. Their relationship with recruiters, either
internal or external, will be important if they are to define the
new, flexible and scalable resourcing models that will enable them to
create highly skilled agile organisations. Increasingly we’ll see
the use of contract resource and interim management resources being
employed to augment core teams or to assist and manage controlled
phases of growth or change. Human Resources will be central to this
vital re-engineering and their ability to architect these changes
will call on the most sophisticated of human resource skills.
These
are two skill areas among many other core functions that are central
to the success drivers of the sector’s companies. So despite the
economic pressures being exerted upon these organisations, we remain
buoyant and optimistic that those people keeping their skills at the
forefront of these functions will remain in demand. It is clear to us
that despite the uncertain outlook that is creeping into many areas
of the market, there are still career development opportunities for
those with the right skills in the right companies.
| About the author |
|
| Additional articles about pharmaceutical executive search |
|
|
| Please Rate This Article |
Number of ratings: 0
Rating: 0